BT3 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Lineage Cell Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.35 EUR

Market Cap: €395.1m

L	Lineage Cell Therapeutics Inc XBER:BT3	US
	California Water Service Group NYSE:CWT	US
T	TJX Companies Inc LSE:0LCE	US
	CuriosityStream Inc NASDAQ:CURI	US

Profitability Summary

Lineage Cell Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

99%

Strong 3Y Average Gross Margin

95%

Gross Margin is Increasing

94% > 99%

Negative Operating Margin

-150%

Negative 3Y Average Operating Margin

-249%

Operating Margin is Increasing

-223% > -150%

Negative Net Margin

-436%

Negative 3Y Average Net Margin

-312%

Declining Net Margin

-209% > -436%

Negative Free Cash Flow Margin

-134%

Negative 3Y Average Free Cash Flow Margin

-267%

Free Cash Flow Margin is Increasing

-304% > -134%

Negative ROE

-103%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-37%

ROIC is Increasing

-36% > -34%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.